Background {#Sec1}
==========

*BRCA1* is a tumor suppressor gene located on chromosome 17, position 17q21 in humans. It is comprised of 24 exons spread over 81 kb of DNA, 22 of which are coding exons. These exons encode a transcript of about 7000 bp translated into a protein of 1863 amino acids \[[@CR1]\]. Exon 11 of *BRCA1* is a large central exon of 3426 bp. This exon represents 60% of the coding sequence.

Nowadays, it is common knowledge that germ-line mutations of the *BRCA1* gene are high risk factors for developing breast cancer \[[@CR2]\]. Since the identification of this particular gene two decades ago \[[@CR3]\], it is now frequently used in prognosis worldwide, in women with breast and ovarian hereditary predisposition syndrome \[[@CR4]\].

Although Sanger sequencing remains the most reliable technique to identify sequence variants, this approach is costly and time consuming. In order to establish an accurate prognosis in breast cancer patients through the identification of *BRCA1* sequence variants, a number of specific screening procedures, which are both cost- and time- effective have been developed \[[@CR1]\].

In Morocco, conventional sequencing techniques have been used to sequence *BRCA1* \[[@CR5],[@CR6]\]. However, sequencing is quite expensive and since Morocco is a low-income country, most of its patients can't afford this type of check-up.

The HRM method is a scanning technique that enables mutation scanning and amplification to be performed readily, and in one step \[[@CR2]\]. This is a method in which only primers and fluorescent DNA binding dye are used, and no sample processing (after PCR amplification) is required \[[@CR7]\]. It is important to note that the HRM technique also allows heteroduplex detection.

Several studies have been conducted to scan *BRCA1* exons by the HRM approach \[[@CR2],[@CR8]-[@CR11]\]. However, to our knowledge, this is the first study performed in Morocco using the HRM approach to screen the *BRCA1* gene.

Our aim was to explore the reliability of the HRM approach for the identification of *BRCA1* mutation carriers in exon 11 among family members of an index patient (IP); and to search for the presence of new genetic variants in the Moroccan population. In the first part of this study, we analyzed and detected, using the HRM approach, variants from samples of patients presenting with breast cancer. In the second part, we corroborated the results (obtained by the HRM method) using the standard Sanger sequencing technique.

Methods {#Sec2}
=======

Patients and samples {#Sec3}
--------------------

We started our work with two previously sequenced, positive controls (2924delA and 3398delC). 71 patients, found positive for breast cancer through clinical and histological examinations, were recruited from private and public oncology centers of Casablanca from 2009 to 2010. Five more donors were used as negative healthy controls.

Experiments performed in this study were evaluated and approved by the Ethic Committee for Biomedical Research in Casablanca (CERBC) of the Faculty of Medicine and Pharmacy (N° 121). For this purpose, a written consent (including the agreement to publish clinical data) was given by each study participant (patient and control).

DNA was extracted using the phenol-chloroform method as previously described, \[[@CR12]\] and quantified using the NanoVue™ Plus Spectrophotometer (GE Healthcare, UK).

HRM protocol {#Sec4}
------------

Assays were performed in 96 well plates. Amplification by PCR, of exon 11 of *BRCA1* was performed using primers reported by P. D. Murphy in 2005 (see Table [1](#Tab1){ref-type="table"}) \[[@CR13]\] using a 7500 Fast Real-Time PCR system (AB Applied Biosystems, USA). Analysis of the obtained curves was performed using the 7500 Fast System SDS v2.0.1 software.Table 1**List of primers used to amplify the** ***BRCA1*** **gene exon 11**GeneSequenceTailleBRCA1Forward primer5' CCACCTCCAAGGTGTATCA-3'372 bpexon 11 AReverse primer5' TGTTATGTTGGCTCCTTGCT-3'BRCA1Forward primer5' CACTAAAGACAGAATGAATCTA-3'400 bpexon 11 BReverse primer5' GAAGAAGCAGAATATTCATCTA-3'BRCA1Forward primer5' TGATGGGGAGTCTGAATCAA-3'400 bpexon 11 CReverse primer5' TCTGCTTTCTTGATAAAATCCT-3'BRCA1Forward primer5' AGCGTCCCCTCACAAATAAA-3'400 bpexon 11 DReverse primer5' TCAAGCGCATGAATATGCCT-3'BRCA1Forward primer5' GTATAAGCAATATGGAACTCGA-3'388 bpexon 11 EReverse primer5' TTAAGTTCACTGGTATTTGAACA-3'BRCA1Forward primer5' GACAGCGATACTTTCCCAGA-3'382 bpexon 11 FReverse primer5' TGGAACAACCATGAATTAGTC-3'BRCA1Forward primer5' GGAAGTTAGCACTCTAGGGA-3'423 bpexon 11 GReverse primer5' GCAGTGATATTAACTGTCTGTA-3BRCA1Forward primer5' TGGGTCCTTAAAGAAACAAAGT-3'366 bpexon 11 HReverse primer5' TCAGGTGACATTGAATCTTCC-3'BRCA1Forward primer5' CCACTTTTTCCCATCAAGTCA-3'377 bpexon 11 IReverse primer5' TCAGGATGCTTACAATTACTTC-3'BRCA1Forward primer5' CAAAATTGAATGCTATGCTTAGA-3'377 bpexon 11 JReverse primer5' TCGGTAACCCTGAGCCAAAT-3'BRCA1Forward primer5' GCAAAAGCGTCCAGAAAGGA-3'396 bpexon 11 KReverse primer5' TATTTGCAGTCAAGTCTTCCAA-3'BRCAForward primer5' GTAATATTGGCAAAGGCATCT-3'360 bpexon 11 LReverse primer5' TAAAATGTGCTCCCCAAAAGCA-3'

In these experiments, we used MeltDoctor ™ HRM Master Mix kit reagents, which contain HRM SYTO9, a DNA intercalating fluorescent agent (BIOLINE, LONDON, UK). The final volume in the reaction mixture is 20 μl (4.4 μl of water, 10 μl of Master Mix, 0.25 μl of each primer (10 μM) and 20 ng of genomic DNA). The HRM protocol was set as follows:One cycle of 95°C for 10 min;40 cycles of 95°C for 10 s, 63°C for 30 s and 72°C for 20 s;One cycle of melt curve of 95°C for 10 s, 60°C for 1 min, 95°C for 15 s and 60°C for 15 s. In these experiments, we used the same Tm of 63°C for all the primers.

DNA sequencing {#Sec5}
--------------

To validate the HRM method, we reanalyzed all of the samples that yielded atypical curves, using conventional Sanger sequencing. These DNA samples were first amplified in a final volume of 25 μl containing: 5× reaction buffer, 1.5 mM MgCl2, 50 μM primers (same primers used for HRM method), 0.25 U Taq polymerase (BIOLINE, LONDON, UK) and 50 ng of genomic DNA.

All the PCR products were treated with exonuclease I and shrimp alkaline phosphatase enzymes prior to sequencing according to the following protocol: 37°C for 40 min and 80°C for 15 min. Then, the obtained PCR products were sequenced using the forward primer, the BigDye Terminator v 1.1Standard Kit (Applied Biosystems, Foster City, CA, USA), and the sequencher 3100 ABI Applied Biosystems. With regard to the analysis, we used the Applied Biosystems SeqScape Software v2.5 SNaPshot analysis.

Results {#Sec6}
=======

The first step of this work was to validate the HRM approach for the entire sequence of the Exon 11 of *BRCA*1 gene. In order to accomplish this, we used DNA samples from five healthy control donors to amplify all these indicated regions. We also used two positive control DNA samples, in which mutations had previously been detected within the region H of exon 11 (see Table [1](#Tab1){ref-type="table"}) \[[@CR5]\]. As expected, all sequence variants in which mutations were previously detected yielded melting curves with abnormal shapes relative to wild-type DNA. In order to corroborate our observation, we sequenced the two samples that exhibited atypical curves, and found that these samples possessed a SNP. Indeed, The B, C, D, E, F, I, K and L regions of exon 11 (see Table [1](#Tab1){ref-type="table"}) did not show atypical curves (Figure [1](#Fig1){ref-type="fig"}); whereas the G and H regions of exon 11 (see Table [1](#Tab1){ref-type="table"}) exhibited different atypical curves (Figures [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). All of these variants have been sequenced except for the samples Br 23 and Br 24, already known to carry mutations in the region H of exon 11 (see Table [2](#Tab2){ref-type="table"} for details).Figure 1**Aligned melt curves of 71 patients.**Figure 2**Difference plots of region H of the** ***BRCA1*** **gene exon 11 between wild-type and c.3279delC and 2805delA mutations (a and b).**Figure 3**Difference plots of region G of the** ***BRCA1*** **gene exon 11 between wild-type and c.2612C \> T SNP (a; b),** **Electropherograms showing sequencing results for c.2612C \> T SNP (c).**Table 2**All mutations and SNPs detected by the HRM approach were validated using Sanger sequencing method**GenePatient codeExonHRM resultSequencing resultMutation typeSystematic nomenclatureSNPManifestation, age at diagnosisFamily historyEthnic originBRCA1Br 2311 HPositivePositivec.2805delA2924delA_BC, 41yM aunt, BC 42 yBerberBr 2411 HPositivePositivec.3279delC3398delC_BC, 32yMother, BC 49 yBerberBr 12311 GPositivePositive\_\_c.2612C \> TBC, 64yNo Family HistoryBerberBr 1211GPositivePositive\_\_c.2612C \> TBC, 27yNo Family HistoryArabBC: Breast Cancer.

Our work has shown that the HRM approach is sensitive, specific and straightforward. This method would also help to avoid costly systematic sequencing. In fact, sequencing, in this case, would be performed only for regions with atypical curves.

Discussion {#Sec7}
==========

In order to detect potential mutations and, at the same time, avoid sequencing the entire *BRCA*1 gene, several alternate methods have been suggested to screen this gene. For instance, De Leener, et al. used the Protein Truncation Test (PTT), denaturing Gradient Gel Electrophoresis (DGGE) and denaturing High-Performance Liquid Chromatography (dHLPC), followed by specific region sequencing \[[@CR8]\]. While all these methods were considered to be relatively sensitive, these approaches, especially the PTT, were shown to be unable to detect all of the mutations \[[@CR11]\]. The purpose of our study was to evaluate the efficacy of the HRM method in screening large sequences for potential mutations.

The High Resolution DNA Melting Analysis was first described by Zhou et al. \[[@CR14]\], where the authors analyzed the ΔF508 mutation associated with the Mucoviscidosis disease. These authors also analyzed, using the same approach, other mutations found in the factor V gene: F508C variants in exon 10; and G551D, G542X, and R553X variants in exon 11.

Regarding *BRCA*1 gene screening by the HRM technique, several groups have reported, in agreement with this work, that this method enables the detection of variants \[[@CR1],[@CR2],[@CR8],[@CR10],[@CR11],[@CR15],[@CR16]\]. In these reports, positive controls were also used to confirm the specificity and sensitivity of this technique \[[@CR1],[@CR2],[@CR8],[@CR10],[@CR11],[@CR15],[@CR16]\]. In 2009, De Juan, et al. used the HRM method followed by sequencing to scan for mutations in the *BRCA*1 and *BRCA*2 genes \[[@CR11]\]. Furthermore, in 2011, the same team reported various advantages of the HRM analysis, and confirmed that this method is much faster than Conformation Sensitive Gel Electrophoresis (CSGE) screening \[[@CR4]\]. Altogether, these reports are in agreement with this study, and indicate that the HRM approach is suitable as a primary screening method of large DNA sequences, especially in diagnosis.

Conclusion {#Sec8}
==========

In the present study, we show that the HRM approach allows for the screening of mutations across large DNA sequences. DNA samples that produce plots which are distinct from the wild-type, should be sequenced to confirm and identify the specific mutations, or SNPs. Finally, we demonstrate that the HRM approach, which is very sensitive, specific, cost-effective, and fast, can be used efficiently, especially in diagnosis.
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